Approaches to the treatment of disease induced by chikungunya virus

Indian Journal of Medical Research

Volumn 138, Issue NOV, 2013, Pages 762-765

  Bettadapura, Jayaram ^a   Herrero, Lara J ^a   Taylor, Adam ^a   Mahalingam, Suresh ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

Antivirals; Arthralgia; Chikungunya; CHIKV; Vaccines

Indexed keywords

BINDARIT; CHLOROQUINE; MANNOSE BINDING LECTIN; PLACEBO; RIBAVIRIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; ANTIVIRUS AGENT; VACCINE;

CHIKUNGUNYA; DRUG SCREENING; HUMAN; IC 50; IMMUNOGENICITY; INFECTION CONTROL; INFECTION RISK; REVIEW; SEQUENCE HOMOLOGY; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS TRANSMISSION; ANTIVIRAL THERAPY; ARTHRALGIA; ARTHRITIS; CHIKUNGUNYA ALPHAVIRUS; DRUG EFFICACY; INFECTION PREVENTION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); VACCINATION;

AEDES; AFRICA; ALPHAVIRUS INFECTIONS; ANIMALS; ANTIVIRAL AGENTS; ASIA, SOUTHEASTERN; CHIKUNGUNYA VIRUS; DISEASE OUTBREAKS; FEVER; HUMANS; INSECT VECTORS; VACCINES;

EID: 84891682880     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Robinson MC. An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952-53. I. Clinical features. Trans R Soc Trop Med Hyg 1955; 49: 28-32.
2. Renault P, Solet, JL, Sissoko D, Balleydier E, Larrieu S, Filleul L, et al. A major epidemic of chikungunya virus infection on Reunion Island, France, 2005-2006. Am J Trop Med Hyg 2007; 77: 727-31.
3. Arankalle VA, Shrivastava S, Cherian S, Gunjikar RS, Walimbe AM, Jadhav SM, et al. Genetic divergence of Chikungunya viruses in India (1963-2006) with special reference to the 2005-2006 explosive epidemic. J Gen Virol 2007; 88: 1967-76.
4. Tsetsarkin KA, Vanlandingham DL, McGee CE, Higgs SA. Single mutation in chikungunya virus affects vector specificity and epidemic potential. PLoS Pathog 2007; 3: e201.
5. Couderc T, Khandoudi N, Grandadam M, Visse C, Gangneux N, Bagot S, et al. Prophylaxis and therapy for Chikungunya virus infection. J Infect Dis 2009; 200: 516-23.
6. Brighton, SW. Chloroquine phosphate treatment of chronic Chikungunya arthritis. An open pilot study. S Afr Med J1984; 66: 217-8.
7. De Lamballerie X, Boisson V, Reynier JC, Enault S, Charrel RN, Flahault A, et al. On chikungunya acute infection and chloroquine treatment. Vector Borne Zoonotic Dis 2008; 8: 837-9.
8. Maheshwari RK, Srikantan V, Bhartiya D. Chloroquine enhances replication of Semliki Forest virus and encephalomyocarditis virus in mice. J Virol 1991;65: 992-5.
9. Ravichandran R, Manian M. Ribavirin therapy for Chikungunya arthritis. J Infect Dev Ctries 2008; 2: 140-2.
10. Briolant S, Garin D, Scaramozzino N, Jouan A, Crance JM. In vitro inhibition of Chikungunya and Semliki Forest viruses replication by antiviral compounds: synergistic effect of interferon-alpha and ribavirin combination. Antiviral Res 2004; 61: 111-7.
11. Rulli NE, Rolph MS, Srikiatkhachorn A, Anantapreecha S, Guglielmotti A, Mahalingam S. Protection from arthritis and myositis in a mouse model of acute chikungunya virus disease by bindarit, an inhibitor of monocyte chemotactic protein-1 synthesis. J Infect Dis 2011; 204: 1026-30.
12. Rulli NE, Guglielmotti A, Mangano G, Rolph MS, Apicella C, Zaid A, et al. Amelioration of alphavirus-induced arthritis and myositis in a mouse model by treatment with bindarit, an inhibitor of monocyte chemotactic proteins. Arthritis Rheum 2009; 60: 2513-23.
13. Pohjala L, Utt A, Varjak M, Lulla A, Merits A, Ahola T, et al. Inhibitors of alphavirus entry and replication identified with a stable Chikungunya replicon cell line and virus-based assays. PLoS One 2011; 6: e28923.
14. Delogu I, Pastorino B, Baronti C, Nougairède A, Bonnet E, de Lamballerie X. In vitro antiviral activity of arbidol against Chikungunya virus and characteristics of a selected resistant mutant. Antiviral Res 2011; 90: 99-107.
15. Kaur P, Thiruchelvan M, Lee RC, Chen H, Chen KC, Ng ML, et al. Inhibition of chikungunya virus replication by harringtonine, a novel antiviral that suppresses viral protein expression. Antimicrob Agents Chemother 2013; 57: 155-67.
16. Bassetto M, De Burghgraeve T, Delang L, Massarotti A, Coluccia A, Zonta N, et al. Computer-aided identification, design and synthesis of a novel series of compounds with selective antiviral activity against chikungunya virus. Antiviral Res 2013; 98: 12-8.
17. Levitt NH, Ramsburg HH, Hasty SE, Repik PM, Cole FE Jr, Lupton HW. Development of an attenuated strain of chikungunya virus for use in vaccine production. Vaccine 1986; 4: 157-62.
18. Edelman R, Tacket CO, Wasserman SS, Bodison SA, Perry JG, Mangiafico JA. Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD 218. Am J Trop Med Hyg 2000; 62: 681-5.
19. Tiwari M, Parida M, Santhosh SR, Khan M, Dash PK, Rao PV. Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus. Vaccine 2009; 27: 2513-22.
20. Akahata W, Yang ZY, Andersen H, Sun S, Holdaway HA, Kong WP, et al. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat Med 2010; 16: 334-8.
21. Muthumani K, Lankaraman KM, Laddy DJ, Sundaram SG, Chung CW, Sako E, et al. Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus. Vaccine 2008; 26: 5128-34.
22. Mallilankaraman K, Shedlock DJ, Bao H, Kawalekar OU, Fagone P, Ramanathan AA, et al. A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl Trop Dis 2011; 5: e928.
23. Weaver SC, Osorio JE, Livengood JA, Chen R, Stinchcomb DT. Chikungunya virus and prospects for a vaccine. Expert Rev Vaccines 2012; 11: 1087-101.
24. Plante K, Wang E, Partidos CD, Weger J, Gorchakov R, Tsetsarkin, K, et al. Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism. PLoS Pathog 2011; 7: e1002142.
25. Chattopadhyay A, Wang E, Seymour R, Weaver SC, Rose JK. A chimeric vesiculo/alphavirus is an effective alphavirus vaccine. J Virol 2013; 87: 395-402.
26. Dash PK, Tiwari M, Santhosh SR, Parida M, Lakshmana Rao PV. RNA interference mediated inhibition of Chikungunya virus replication in mammalian cells. Biochem Biophys Res Commun 2008; 376: 718-22.
27. Lam S, Chen KC, Ng MM, Chu JJ, Expression of plasmid-based shRNA against the E1 and nsP1 genes effectively silenced Chikungunya virus replication. PLoS One 2012; 7: e46396.
28. Gunn BM, Morrison TE, Whitmore AC, Blevins LK, Hueston L, Fraser RJ, et al. Mannose binding lectin is required for alphavirus-induced arthritis/myositis. PLoS Pathog 2012; 8: e1002586.
29. Shoji-Kawata S, Sumpter R, Leveno M, Campbell GR, Zou Z, Kinch L, et al. Identification of a candidate therapeutic autophagy-inducing peptide. Nature 2013; 494: 201-6.
30. Nakaya HI, Gardner J, Poo YS, Major L, Pulendran B, Suhrbier A. Gene profiling of Chikungunya virus arthritis in a mouse model reveals significant overlap with rheumatoid arthritis. Arthritis Rheum 2012; 64: 3553-63.